SG10201604093XA - Antibody formulation and therapeutic regimens - Google Patents

Antibody formulation and therapeutic regimens

Info

Publication number
SG10201604093XA
SG10201604093XA SG10201604093XA SG10201604093XA SG10201604093XA SG 10201604093X A SG10201604093X A SG 10201604093XA SG 10201604093X A SG10201604093X A SG 10201604093XA SG 10201604093X A SG10201604093X A SG 10201604093XA SG 10201604093X A SG10201604093X A SG 10201604093XA
Authority
SG
Singapore
Prior art keywords
therapeutic regimens
antibody formulation
antibody
formulation
regimens
Prior art date
Application number
SG10201604093XA
Other languages
English (en)
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H Salinger
Scott Walter Baumgartner
Christopher J Endres
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201604093X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of SG10201604093XA publication Critical patent/SG10201604093XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
SG10201604093XA 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens SG10201604093XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10

Publications (1)

Publication Number Publication Date
SG10201604093XA true SG10201604093XA (en) 2016-07-28

Family

ID=43858045

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201604093XA SG10201604093XA (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens
SG2012051108A SG182468A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012051108A SG182468A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Country Status (37)

Country Link
US (5) US8883151B2 (fr)
EP (3) EP2523688B1 (fr)
JP (2) JP5743234B2 (fr)
KR (1) KR101766936B1 (fr)
CN (1) CN102821787B (fr)
AR (1) AR079903A1 (fr)
AU (3) AU2011205402B2 (fr)
BR (1) BR112012017150B1 (fr)
CA (1) CA2787128C (fr)
CL (1) CL2012001966A1 (fr)
CO (1) CO6640206A2 (fr)
CR (1) CR20120419A (fr)
CY (2) CY1119852T1 (fr)
DK (2) DK3295957T3 (fr)
EA (2) EA201891433A3 (fr)
ES (2) ES2652637T3 (fr)
HR (1) HRP20171939T1 (fr)
HU (2) HUE035618T2 (fr)
IL (1) IL220602B (fr)
IN (1) IN2012DN06720A (fr)
LT (2) LT2523688T (fr)
MA (1) MA33989B1 (fr)
MX (1) MX349856B (fr)
MY (1) MY182680A (fr)
NO (1) NO2523688T3 (fr)
NZ (1) NZ601125A (fr)
PE (1) PE20121691A1 (fr)
PL (2) PL2523688T3 (fr)
PT (2) PT2523688T (fr)
RS (2) RS56781B1 (fr)
SG (2) SG10201604093XA (fr)
SI (2) SI2523688T1 (fr)
TN (1) TN2012000335A1 (fr)
TW (1) TWI554282B (fr)
UA (1) UA112288C2 (fr)
WO (1) WO2011088120A1 (fr)
ZA (1) ZA201205167B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
ES2652637T3 (es) * 2010-01-15 2018-02-05 Kirin-Amgen, Inc. Formulación de anticuerpos y regímenes terapéuticos
EP2531218B1 (fr) * 2010-02-04 2018-12-12 CSL Behring AG Préparation d'immunoglobuline
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
SG188591A1 (en) 2010-09-22 2013-04-30 Amgen Inc Carrier immunoglobulins and uses thereof
AU2012240050B2 (en) * 2011-04-07 2016-01-21 Glaxosmithkline Llc Formulations with reduced viscosity
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013016220A1 (fr) * 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
AU2012340621B2 (en) * 2011-11-23 2017-10-12 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
JP6117252B2 (ja) * 2012-03-07 2017-04-19 イーライ リリー アンド カンパニー Ｉｌ−１７抗体製剤
ES2622558T3 (es) 2012-05-14 2017-07-06 Novo Nordisk A/S Soluciones proteínicas estabilizadas
US20160060337A1 (en) 2013-03-15 2016-03-03 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
NZ712294A (en) 2013-03-15 2020-04-24 Amgen Inc Methods for treating crohn’s disease using an anti-il23 antibody
KR102530900B1 (ko) * 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
EP3143404B1 (fr) 2014-05-16 2018-08-29 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
MY186840A (en) * 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
US10620177B2 (en) * 2014-09-10 2020-04-14 Nof Corporation Protein adsorption inhibitor and method for inhibiting protein adsorption
US11016099B2 (en) 2015-09-17 2021-05-25 Amgen Inc. Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers
AU2016349113A1 (en) 2015-11-04 2018-06-07 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
CA3007098A1 (fr) 2015-12-22 2017-06-29 Amgen Inc Ccl20 en tant que predicteur de reponse clinique aux antagonistes d'il23
EP3446178A4 (fr) 2016-04-19 2020-01-22 Sage Electrochromics, Inc. Dispositif électrochromique comprenant une couche d'oxyde conductrice transparente et une barre omnibus et son procédé de formation
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (fr) * 2017-07-26 2019-01-26 Michael Giroux Ancrage de securite et event de toit
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20210277105A1 (en) 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
WO2021050563A1 (fr) * 2019-09-09 2021-03-18 The Rockefeller University Traitement par anticorps pour le tissu lésionnel de l'hidradénite suppurée
US20220380449A1 (en) 2019-09-11 2022-12-01 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
CN112891531B (zh) * 2020-06-19 2021-10-08 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
KR20240021800A (ko) * 2021-05-12 2024-02-19 아납티스바이오, 아이엔씨. 항체 조성물
WO2023240071A1 (fr) * 2022-06-06 2023-12-14 Fusion Pharmaceuticals Inc. Méthodes de dosage d'agents thérapeutiques

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
CA2017025C (fr) 1989-05-18 2008-07-22 David Wallach Proteine de liaison ii du facteur de necrose des tumeurs, sa purification et les anticorps diriges contre elle
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
CA2032191C (fr) 1989-12-13 1999-05-18 David Wallach Expression de la proteine recombinante liant le facteur de necrose des tumeurs
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
ES2251009T3 (es) 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
WO1992001002A1 (fr) 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
EP0567566B2 (fr) 1991-01-18 2007-07-04 Amgen Inc., Procedes pour traiter les maladies induites par facteur de necrose tumorale
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
AU674292B2 (en) 1991-10-15 1996-12-19 Immunex Corporation Methods and compositions for treating allergic reactions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
CA2122732C (fr) 1991-11-25 2008-04-08 Marc D. Whitlow Proteines multivalentes fixatrices d'antigenes
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
ATE188610T1 (de) 1992-04-30 2000-01-15 Amgen Inc Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
CA2123593C (fr) 1992-09-15 2000-03-14 Craig A. Smith Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
ES2229264T5 (es) 1995-03-23 2009-12-17 Immunex Corporation Receptor il-17.
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
CA2227220A1 (fr) 1995-07-19 1997-02-06 Genetics Institute, Inc. Proteines humaines ctla-8 et utilisation de proteines apparentees aux proteines ctla-8
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
EP0959897B1 (fr) 1996-11-27 2009-04-22 Immunex Corporation Procede permettant de reguler la production de monoxyde d'azote
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE442385T1 (de) 1997-09-17 2009-09-15 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
HU227347B1 (en) 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
AU2001247545A1 (en) 2000-03-16 2001-09-24 Amgen Inc. Il-17 receptor like molecules and uses thereof
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2004517918A (ja) 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
DK1946776T3 (en) 2002-02-27 2017-03-13 Immunex Corp STABILIZED TNFR-FC COMPOSITION COMPREHENSIVE ARGININE
WO2004002519A1 (fr) 2002-06-27 2004-01-08 Smithkline Beecham Corporation Methodes de traitement ou de prevention de maladies intestinales inflammatoires a l'aide d'il-18
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050070460A1 (en) 2003-08-05 2005-03-31 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
ES2553987T3 (es) 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
CN101014664B (zh) 2004-06-04 2012-10-10 设计者分子公司 可自由基固化的聚酯及其使用方法
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101160528A (zh) 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
CA2615122A1 (fr) 2005-08-03 2007-02-15 Immunogen, Inc. Formulations d'immunoconjugue
CA2618068C (fr) 2005-08-05 2016-02-16 Amgen Inc. Formulations pharmaceutiques de proteine aqueuse stable ou d'anticorps et leur preparation
ATE445415T1 (de) 2005-09-01 2009-10-15 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
CA2624763A1 (fr) 2005-10-18 2007-04-26 Zymogenetics, Inc. Antagonistes de il-17c et methodes d'utilisation desdits antagonistes
CA2626531C (fr) 2005-11-01 2011-11-29 Wyeth Solution de chlorure de sodium pour la reconstitution ou la dilution de medicaments
EP1977763A4 (fr) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Préparation stabilisatrice contenant des anticorps
WO2007092772A2 (fr) 2006-02-03 2007-08-16 Medimmune, Inc. Formulations de protéines
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
WO2008049070A2 (fr) 2006-10-18 2008-04-24 Zymogenetics, Inc. Antagonistes de l'il-17c et leurs procédés d'utilisation
WO2008079290A2 (fr) * 2006-12-21 2008-07-03 Amgen Inc Formulations
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2679588A1 (fr) 2007-03-26 2008-10-02 Zymogenetics, Inc. Proteines de fusion solubles il-17ra/rc et procedes afferents
AU2008266948B2 (en) 2007-06-13 2012-08-23 Kirin-Amgen, Inc. IL-17 heteromeric receptor complex
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
JP2010536786A (ja) 2007-08-17 2010-12-02 アムジエン・インコーポレーテツド ポリカチオンを用いた抗体およびｆｃ融合分子の製剤
MY184345A (en) 2008-02-21 2021-04-01 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
ES2652637T3 (es) 2010-01-15 2018-02-05 Kirin-Amgen, Inc. Formulación de anticuerpos y regímenes terapéuticos
BR112013008501A2 (pt) 2010-10-08 2016-08-16 Novartis Ag métodos para o tratamento de psoríase usando anatgonistas de il-17
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
WO2012141978A2 (fr) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations à viscosité réduite
AU2012240050B2 (en) * 2011-04-07 2016-01-21 Glaxosmithkline Llc Formulations with reduced viscosity
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
MY186840A (en) 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
EA201290653A1 (ru) 2013-02-28
AR079903A1 (es) 2012-02-29
JP2015052017A (ja) 2015-03-19
PT3295957T (pt) 2019-11-12
US10072085B2 (en) 2018-09-11
JP5743234B2 (ja) 2015-07-01
BR112012017150B1 (pt) 2022-03-03
US8883151B2 (en) 2014-11-11
IL220602B (en) 2019-03-31
DK3295957T3 (da) 2019-10-14
CY1119852T1 (el) 2018-06-27
ZA201205167B (en) 2013-03-27
EA031209B9 (ru) 2021-11-19
TN2012000335A1 (en) 2013-12-12
DK2523688T3 (en) 2017-12-04
EP3295957B1 (fr) 2019-08-07
PL3295957T3 (pl) 2020-03-31
EP2523688A1 (fr) 2012-11-21
PT2523688T (pt) 2018-01-05
PL2523688T3 (pl) 2018-04-30
EP2523688B1 (fr) 2017-10-11
AU2011205402B2 (en) 2015-02-05
CN102821787B (zh) 2015-07-29
KR20120118036A (ko) 2012-10-25
JP2013517277A (ja) 2013-05-16
MX349856B (es) 2017-08-16
EA031209B1 (ru) 2018-12-28
WO2011088120A8 (fr) 2012-09-13
AU2015202023B2 (en) 2017-05-18
US10808033B2 (en) 2020-10-20
EA201891433A2 (ru) 2018-11-30
CA2787128C (fr) 2019-06-11
EP3295957A1 (fr) 2018-03-21
KR101766936B1 (ko) 2017-08-09
EP3632466A1 (fr) 2020-04-08
LT2523688T (lt) 2018-03-12
US11505612B2 (en) 2022-11-22
CL2012001966A1 (es) 2013-01-18
US20180346583A1 (en) 2018-12-06
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
MA33989B1 (fr) 2013-02-01
HUE046670T2 (hu) 2020-03-30
MY182680A (en) 2021-01-29
PE20121691A1 (es) 2012-12-14
CA2787128A1 (fr) 2011-07-21
ES2753216T3 (es) 2020-04-07
SG182468A1 (en) 2012-08-30
WO2011088120A1 (fr) 2011-07-21
SI3295957T1 (sl) 2020-02-28
US20230192873A1 (en) 2023-06-22
CN102821787A (zh) 2012-12-12
US20150017184A1 (en) 2015-01-15
ES2652637T3 (es) 2018-02-05
CY1122466T1 (el) 2020-10-14
CR20120419A (es) 2012-11-29
AU2015202023A1 (en) 2015-05-14
TW201129382A (en) 2011-09-01
WO2011088120A9 (fr) 2012-08-09
BR112012017150A2 (pt) 2017-10-10
UA112288C2 (uk) 2016-08-25
NO2523688T3 (fr) 2018-03-10
AU2017216579A1 (en) 2017-09-07
HRP20171939T1 (hr) 2018-03-23
US20200399384A1 (en) 2020-12-24
MX2012008213A (es) 2012-11-06
EA201891433A3 (ru) 2019-02-28
LT3295957T (lt) 2020-01-27
TWI554282B (zh) 2016-10-21
CO6640206A2 (es) 2013-03-22
AU2011205402A1 (en) 2012-07-12
RS59743B1 (sr) 2020-02-28
RS56781B1 (sr) 2018-04-30
HUE035618T2 (en) 2018-05-28
IN2012DN06720A (fr) 2015-10-23
NZ601125A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
ZA201205167B (en) Antibody formulation and therapeutic regimens
RS63063B1 (sr) Anti-ngf antitela i njihova upotreba
EP2542086A4 (fr) Composés et utilisations thérapeutiques associées
IL221511A (en) Arilatriazolones associated with bis aryl and their use
HK1201454A1 (en) Therapeutic agents and uses thereof
IL223667B (en) 4a100s antibodies and medical uses thereof
ZA201300930B (en) St-246 liquid formulations and methods
HRP20160929T1 (hr) Terapijski režimi
EP2718283A4 (fr) Dérivé d'indazole et pyrrolopyridine et utilisation pharmaceutique de celui-ci
PT2521445T (pt) Formulação e utilização da mesma
GB201011411D0 (en) Therapeutic compounds and their use
PT2563806E (pt) Leucolectinas humanas e suas utilizações
EP2620449A4 (fr) Anticorps dirigé contre l'éphrine b2 et utilisation correspondante
AP2014007616A0 (en) Agrochemical formulation and use thereof
EP2578682A4 (fr) Anticorps et son utilisation
GB201003741D0 (en) Methods and therapeutic compositions
GB201012660D0 (en) Inhaler and formulation
GB201002451D0 (en) Pharmaceutical comopitions and devices
GB201112578D0 (en) Pharmaceutical preparation and use